Business
Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS)
Oral presentation highlights TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in Phase 3 RESILIENT study demonstrating statistically significant
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"Oral presentation highlights TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in Phase 3 RESILIENT study demonstrating statistically significant improvement in fibromyalgia nociplastic pain and in all six key secondary endpoints, including sleep quality Posters highlighting other TNX-102 SL programs in clinical development, including acute stress disorder Poster demonstrating automated high-throughput assay enabling screening for therapeutics to accelerate wound healing CHATHAM, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that representatives of the Company will deliver an oral presentation and present three posters at the 2024 Military Health System Research Symposium (MHSRS), being held August 26-29, 2024, in Kissimmee, Fla. Details on the presentations can be found below. Copies of the Company’s oral presentation and posters will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the MHSRS website here. Oral Presentation Presenter:Seth Lederman, M.D., Chief Executive Officer of Tonix PharmaceuticalsSession:Assuaging Agony: Novel Pain TherapeuticsTitle:Efficacy and Safety of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) for the Management of Fibromyalgia: Results from the Confirmatory Phase 3 Randomized, Double-Blind, Placebo-Controlled RESILIENT TrialDate/Time:Tuesday, August 27, 2024, 1:00 p.m. – 3:00 p.m. ET Poster Presentations Presenter:Megan Parmenter, Ph.D., Massachusetts General HospitalTitle: Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSDDate/Time:Tuesday, August 27, 2024, 3:00 p.m. – 5:00 p.m. ET Presenter:Sina Bavari, Ph.D., EVP, Infectious Disease Research and Development, Tonix PharmaceuticalsTitle: Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound HealingDate/Time:Wednesday, August 28, 2024, 1:00 p.m. - 3:00 p.m. ET Presen...